Screener
Taysha Gene Therapies, Inc. TSHA Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-207666
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Other (expense) income: | ||
| Change in fair value of warrant liability | — | 102 |
| Change in fair value of term loan | (1,470) | (1,530) |
| Interest income | 2,586 | 1,326 |
| Interest expense | (9) | (19) |
| Other income (expense) | (31) | 13 |
| Total other income (expense), net | 1,076 | (108) |
| Net loss | $(42,410) | $(21,529) |
Item 1. Financial Statements.
FAQ
- What is Taysha Gene Therapies, Inc.'s interest income?
- Taysha Gene Therapies, Inc. (TSHA) reported interest income of $2.59M in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s interest income changed year-over-year?
- Taysha Gene Therapies, Inc.'s interest income increased by 95.0% year-over-year, from $1.33M to $2.59M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Taysha Gene Therapies, Inc.'s interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude